Sandoz Signed Agreement for Hemlibra Biosimilar
The company partnered with mAbxience to develop a version of the treatment for hemophilia A.
Updated on Oct. 13, 2026 in Biotech
Live Poll
Do you believe collaborations between pharmaceutical companies to create biosimilars ultimately benefit patients?
On September 18, 2026, Sandoz announced a development and commercialization agreement with mAbxience for a biosimilar to Genentech HEMLIBRA. This treatment is currently used for patients with hemophilia A.
Why it matters
This collaboration allows Sandoz to expand its biosimilar portfolio, which now includes 40 distinct assets. The deal leverages the manufacturing capabilities of mAbxience alongside the global commercial reach of Sandoz.
The agreement covers the development of a biosimilar to HEMLIBRA, a treatment utilized for hemophilia A. This partnership brings the total number of assets in the Sandoz biosimilar pipeline to 40.
The players
Sandoz
This global pharmaceutical company specializes in the development and distribution of biosimilar medicines.
mAbxience
This firm is a biotechnology company focused on the development and manufacturing of complex biological medicines.
Genentech
This biotechnology corporation is the developer of the hemophilia A drug HEMLIBRA.
The details
Under the terms of the deal, mAbxience handles all development and manufacturing processes for the biosimilar. Sandoz retains exclusive commercialization rights globally, with the exception of operations in Argentina, Uruguay, and Paraguay.
Timeline
Sandoz and mAbxience announced the biosimilar agreement on September 18, 2026.
The Tech Race
The expansion of the Sandoz biosimilar pipeline reflects the market pathways established by the Biologics Price Competition and Innovation Act. This move intensifies the race among pharmaceutical firms to provide alternatives to high-cost specialty biological therapies.
The introduction of a biosimilar version of a costly specialty drug could lead to increased market competition and potential price reductions for healthcare providers. Patients currently relying on hemophilia A treatments may see greater access to therapy options as more products enter the market.
The takeaway
This partnership highlights the industry trend toward building massive biosimilar pipelines to challenge established biologic market shares. Future collaboration between the two companies remains possible as they continue to refine their shared product development strategy.
Further reading
For more information on the evolving landscape of biological treatments, visit the Biotech section.
Source note: This article includes information reported by Big Molecule Watch.
Live Poll
Do you believe collaborations between pharmaceutical companies to create biosimilars ultimately benefit patients?
